Prenatal alcohol exposure influences the effects of neuroactive steroids on separation-induced ultrasonic vocalizations in rat pups.
Fetal alcohol exposure has been reported to be associated with hyper-responsiveness to stress. Using a maternal separation paradigm, this study examined whether prenatal alcohol exposure affected sensitivity to neurosteroid modulation of stress. We have shown that the neuroactive steroid allopregnanolone reduces ultrasonic vocalizations (USVs) after brief maternal separation in week-old rat pups. Prenatal alcohol exposure, however, resulted in reduced sensitivity to this neurosteroid. In this study's first experiment, the behavioral effects of pregnenolone sulfate, a neurosteroid with reportedly opposite modulatory effects on the GABAA receptor, were characterized. Pregnenolone sulfate had a triphasic effect on the production of ultrasonic vocalizations and on open field activity. Blockade of conversion of pregnenolone sulfate to allopregnanolone via the 5 alpha-reductase inhibitor 4-MA also blocked the drug-related reduction in USVs, but not the higher-dose augmentation. The enzyme inhibitor alone had no significant effects on USV production, nor did progesterone. These results suggest that the neuroactive steroid pregnenolone sulfate may play an independent role in the stress response after maternal separation as well as being a precursor for the anxiolytic neurosteroid allopregnanolone. In the second experiment, prenatal alcohol exposure was found to eliminate both the low dose USV-reducing effect and the higher dose USV-increasing effect. These results support previous results demonstrating that prenatal alcohol exposure may cause an altered sensitivity to the neuromodulatory effects of neurosteroids.
Zimmerberg
B
B
Department of Psychology, Bronfman Science Center, Williams College, Williamstown, MA 01267, USA.
McDonald
B C
BC
D000726:Androgen Antagonists / Q000494:pharmacology; D000818:Animals; D001010:Anxiety, Separation / Q000523:psychology*; D001378:Azasteroids / Q000494:pharmacology; D002492:Central Nervous System Depressants / Q000633:toxicity*; D042944:Cholestenone 5 alpha-Reductase; D013196:Dihydrotestosterone / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D000431:Ethanol / Q000633:toxicity*; D005260:Female; D010088:Oxidoreductases / Q000037:antagonists & inhibitors; D011247:Pregnancy; D011284:Pregnenolone / Q000494:pharmacology; D011297:Prenatal Exposure Delayed Effects; D011374:Progesterone / Q000494:pharmacology; D051381:Rats; D013256:Steroids / Q000494:pharmacology*; D014828:Vocalization, Animal / Q000187:drug effects*
D000726:Androgen Antagonists; D001378:Azasteroids; D002492:Central Nervous System Depressants; D013256:Steroids; D013196:Dihydrotestosterone; D000431:Ethanol; D011374:Progesterone; C031563:17-N,N-diethylcarbamoyl-4-methyl-4-azaandrostane-3-one; D011284:Pregnenolone; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase